Patents by Inventor Akinola Soyode-Johnson

Akinola Soyode-Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20210017168
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: January 21, 2021
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Akinola SOYODE-JOHNSON, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • P2X7 Modulators
    Publication number: 20200325138
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
    Patent number: 10766880
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: September 8, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • P2X7 modulators
    Patent number: 10703749
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: July 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators
    Patent number: 10617676
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: April 14, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C Chrovian, Michael A Letavic, Jason C Rech, Dale A Rudolph, Akinola Soyode-Johnson, Brice M Stenne, Jessica L Wall
  • Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
    Publication number: 20200048263
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: October 15, 2019
    Publication date: February 13, 2020
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
  • Substituted 4-azaindoles and their use as GluN2B receptor modulators
    Patent number: 10377753
    Abstract: Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 13, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Jessica L. Wall
  • SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS
    Publication number: 20190135791
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: December 31, 2018
    Publication date: May 9, 2019
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • P2X7 Modulators
    Publication number: 20190092770
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 28, 2019
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
    Patent number: 10233173
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: March 19, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • P2X7 modulators
    Patent number: 10150765
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: December 11, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS
    Publication number: 20180334451
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: July 26, 2018
    Publication date: November 22, 2018
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • P2X7 modulators and methods of use
    Patent number: 10112937
    Abstract: The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 30, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Manuel Jesus Alcazar Vaca, Brett D. Allison, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Xiaohu Deng, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Jimmy T. Liang, Neelakandha S. Mani, Jason C. Rech, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson, Jessica L. Wall
  • Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
    Patent number: 10071988
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: September 11, 2018
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20180208595
    Abstract: Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: March 20, 2018
    Publication date: July 26, 2018
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson
  • SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
    Publication number: 20180125826
    Abstract: Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: October 5, 2017
    Publication date: May 10, 2018
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode-Johnson, Brice M. Stenne, Jessica L. Wall
  • Substituted 4-azaindoles and their use as GluN2B receptor modulators
    Patent number: 9963447
    Abstract: Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 8, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Jessica L. Wall
  • P2X7 MODULATORS
    Publication number: 20180118749
    Abstract: The present invention is directed to compounds of Formula (I), which includes enantiomer and diasteromers thereof: These compounds are suitable for use in the treatment of diseases associated with P2X7 receptor activity such as diseases of the autoimmune and inflammatory system, diseases of the nervous and neuro-immune system, diseases involved with neuroinflammation of the Central Nervous System (CNS) or diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems.
    Type: Application
    Filed: August 26, 2015
    Publication date: May 3, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Jose Ignacio ANDRES GIL, Christa C. Chrovian, Michael A. Letavic, Jason C. Rech, Dale A. Rudolph, Akinola Soyode Johnson
  • SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS
    Publication number: 20170226089
    Abstract: Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
    Type: Application
    Filed: February 9, 2017
    Publication date: August 10, 2017
    Inventors: Gang Chen, Christa C. Chrovian, Heather R. Coate, Curt A. Dvorak, Christine F. Gelin, Afton Hiscox, Michael A. Letavic, Jason C. Rech, Akinola Soyode-Johnson, Brice Stenne, Jessica L. Wall, Wei Zhang
  • Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators
    Publication number: 20170129901
    Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 11, 2017
    Inventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson